Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $82 | 5 days |
Description | PF-05180999 is an inhibitor of phosphodiesterase 2A (IC50: 1.6 nM). |
Targets&IC50 | PDE7B:50.09 μM, PDE2A:1.6 nM, PDE11A4:26.969 μM, PDE10A1:2.03 μM |
In vitro | PF-05180999 is also a weak inducer of CYP3A4, and with no direct inhibition of human recombinant cytochrome P450 (CYP) enzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A) and no induction of CYP1A2. PF-05180999 binds to the rat, dog and monkey PDE2A (Kis: 4.2, 8.4, and 5.5 nM and IC50s: 2.6, 5.2, and 3.4 nM, respectively). PF-05180999 displays weak activity against PDE, with IC50s of 2.03 μM (PDE10A1), 26.969 μM (PDE7B), 50.09 μM (PDE11A4), and >56.25 μM (PDE1B1, PDE3A1, PDE4D3, PDE5A1, PDE6 (bovine), PDE8B, PDE9A1), respectively [1]. |
In vivo | PF-05180999 triggers an immediate and dose-dependent increase in cGMP levels in the cortex, striatum, and hippocampus without affecting cAMP levels or the downstream phospho-cAMP response element-binding protein (p-CREB) in mice. At doses of 0.032-0.32 mg/kg, administered subcutaneously, it significantly reduces working memory errors caused by ketamine in a rat working memory radial arm maze (RAM) model [1]. |
Molecular Weight | 414.39 |
Formula | C19H17F3N8 |
Cas No. | 1394033-54-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (120.66 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.